Toward characterization and definition of fibromyalgia severity

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Silverman, Stuart ^a   Sadosky, Alesia ^b   Evans, Chris ^c   Yeh, Yating ^c   Alvir, Jose Ma J ^b   Zlateva, Gergana ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c MAPI VALUES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; BACKACHE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MEDICAL SPECIALIST; NECK PAIN; PAIN ASSESSMENT; RATING SCALE; SELF CONCEPT; SELF REPORT; SLEEP DISORDER; STRUCTURED QUESTIONNAIRE; DAILY LIFE ACTIVITY; DISABILITY; EVALUATION; EXPERT WITNESS; HOSPITALIZATION; INTRACTABLE PAIN; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SELF EVALUATION;

ANALGESIC AGENT;

ACTIVITIES OF DAILY LIVING; ADULT; ANALGESICS; COMORBIDITY; DISABILITY EVALUATION; EXPERT TESTIMONY; FATIGUE; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PAIN, INTRACTABLE; QUALITY OF LIFE; QUESTIONNAIRES; SELF ASSESSMENT (PSYCHOLOGY); SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS;

EID: 77950632865     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-66     Document Type: Article

References (35)

1. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. F Wolfe HA Smythe MB Yunus RM Bennett C Bombardier DL Goldenberg P Tugwell SM Campbell M Abeles P Clark, et al. Arthritis Rheum 1990 33 2 160 172 10.1002/art.1780330203 2306288 (Pubitemid 20098653)
2. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. RC Lawrence DT Felson CG Helmick LM Arnold H Choi RA Deyo S Gabriel R Hirsch MC Hochberg GG Hunder, et al. Arthritis Rheum 2008 58 1 26 35 10.1002/art.23176 18163497
3. Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient delphi exercises. PJ Mease LM Arnold LJ Crofford DA Williams IJ Russell L Humphrey L Abetz SA Martin, Arthritis Rheum 2008 59 7 952 960 10.1002/art.23826 18576290 (Pubitemid 351990991)
4. Characteristics and healthcare costs of patients with fibromyalgia syndrome. A Berger E Dukes S Martin J Edelsberg G Oster, Int J Clin Pract 2007 61 9 1498 1508 10.1111/j.1742-1241.2007.01480.x 17655684 (Pubitemid 47228612)
5. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. DL Hoffman E Dukes, Int J Clin Pract 2007 62 1 115 126 10.1111/j.1742-1241.2007.01638.x 18039330 (Pubitemid 350294025)
6. Disability and quality of life in patients with fibromyalgia. JA Verbunt DH Pernot RJ Smeets, Health Qual Life Outcomes 2008 6 8 10.1186/1477-7525-6-8 18211701
7. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. LA White HG Birnbaum A Kaltenboeck J Tang D Mallett RL Robinson, J Occup Environ Med 2008 50 1 13 24 10.1097/JOM.0b013e31815cff4b 18188077
8. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. The London Fibromyalgia Epidemiology Study. KP White M Speechley M Harth T Ostbye, Arthritis Rheum 1999 42 1 76 83 10.1002/1529-0131(199901)42:1<76::AID-ANR103. 0.CO;2-G 9920017 (Pubitemid 29042573)
9. Urinary markers of altered collagen metabolism in fibromyalgia patients. S Ribel-Madsen S Christgau ST Gronemann EM Bartels B Danneskiold-Samsøe H Bliddal, Scand J Rheumatol 2007 36 6 47 477 10.1080/03009740701483048 (Pubitemid 350293530)
10. Antipolymer antibody in Italian fibromyalgic patients. L Bazzichi C Giacomelli F De Feo T Giuliano A Rossi M Doveri C Tani RB Wilson S Bombardieri, Arthritis Res Ther 2007 9 5 86 10.1186/ar2285 17822528 (Pubitemid 47528097)
11. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. L Bazzichi A Rossi G Massimetti G Giannaccini T Giuliano F De Feo A Ciapparelli L Dell'Osso S Bombardieri, Clin Exp Rheumatol 2007 25 2 225 230 17543146 (Pubitemid 46851426)
12. Anti-polymer antibodies are correlated with pain and fatigue severity in patients with fibromyalgia syndrome. P Sarzi-Puttini F Atzeni M Di Franco N Lama A Batticciotto C Iannuccelli D Dell'Acqua S de Portu V Riccieri M Carrabba, et al. Autoimmunity 2008 41 1 74 79 10.1080/08916930701620035 18176867
13. Tender point count and total myalgic score in fibromyalgia: changes over a 28-day period. JG McVeigh MB Finch DA Hurley JR Basford J Sim GD Baxter, Rheumatol Int 2007 27 11 1011 1018 10.1007/s00296-007-0404-8 17641895 (Pubitemid 47246593)
14. Which of the three different tender points assessment methods is more useful for predicting the severity of fibromyalgia syndrome? N Tastekin M Birtane K Uzunca, Rheumatol Int 2007 27 5 447 451 10.1007/s00296-006-0232-2 17028859 (Pubitemid 46294979)
15. Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. D Dadabhoy LJ Crofford M Spaeth IJ Russell DJ Clauw, Arthritis Res Ther 2008 10 211 10.1186/ar2443 18768089
16. Health status and disease severity in fibromyalgia. Results of a six-center longitudinal study. F Wolfe J Anderson D Harkness RM Bennett XJ Caro DL Goldenberg IJ Russell MB Yunus, Arthritis Rheum 1997 40 9 1571 1579 10.1002/art.1780400905 9324010 (Pubitemid 27426149)
17. Classification, epidemiology, and natural history of fibromyalgia. KP White M Harth, Curr Pain Headache Rep 2001 5 320-329 11403735
18. The fibromyalgia impact questionnaire: development and validation. CS Burckhardt SR Clark RM Bennett, J Rheumatol 1991 18 5 728 733 1865419
19. Responsiveness of fibromyalgia clinical trial outcomes measures. PR Dunkl AG Taylor GG McConnell AP Alfano MR Conaway, J Rheumatol 2000 27 2683 2691 11093454
20. A model to assess severity and impact of fibromyalgia. DL Goldenberg CJ Mossey CH Schmid, J Rheumatol 1995 22 2313 2318 8835568
21. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. T Giesecke DA Williams RE Harris TR Cupps X Tian TX Tian RH Gracely DJ Clauw, Arthritis Rheum 2003 48 10 2916 2922 10.1002/art.11272 14558098 (Pubitemid 37280621)
22. Validation of a modified version of the Brief Pain Inventory for painful diabetic peripheral neuropathy. DC Zelman M Gore E Dukes K-S Tai N Brandenburg, J Pain Symptom Manage 2005 29 4 401 410 10.1016/j.jpainsymman.2004.06.018 15857744 (Pubitemid 40602521)
23. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. D Zelman E Dukes N Brandenburg A Bostrom M Gore, Pain 2005 115 2 29 36 10.1016/j.pain.2005.01.028 15836967 (Pubitemid 40503963)
24. Fibromyalgia syndrome. P Mease LM Arnold R Bennett A Boonen D Buskila S Carville A Chappell E Choy D Clauw D Dadabhoy, et al. J Rheumatol 2007 34 6 1415 1425 17552068 (Pubitemid 46898129)
25. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. DC Turk RH Dworkin LB Burke R Gershon M Rothman J Scott RR Allen JH Atkinson J Chandler C Cleeland, et al. Pain 2006 125 3 208 215 10.1016/j.pain.2006.09.028 17069973 (Pubitemid 44711972)
26. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. T Pincus V Strand G Koch I Amara B Crawford F Wolfe S Cohen D Felson, Arthritis Rheum 2003 48 3 625 630 10.1002/art.10824 12632413 (Pubitemid 36301996)
27. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. V Strand S Cohen B Crawford JS Smolen DL Scott Leflunomide Investigators Groups, Rheumatology (Oxford) 2004 43 5 640 647 10.1093/rheumatology/keh140 15039493 (Pubitemid 38628197)
28. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. T Pincus C Chung OG Segurado I Amara GG Koch, J Rheumatol 2006 33 11 2146 2152 17080518 (Pubitemid 44749771)
29. A prospective long-term study of fibromyalgia syndrome. M Kennedy DT Felson, Arthritis Rheum 1996 39 4 682 685 10.1002/art.1780390422 8630121 (Pubitemid 26118048)
30. Sleep disturbances in fibromyalgia syndrome: Relationship to pain and depression. SM Bigatti AM Hernandez TA Cronan KL Rand, Arthritis Rheum 2008 59 7 961 967 10.1002/art.23828 18576297
31. Patient perspectives on the impact of fibromyalgia. LM Arnold LJ Crofford PJ Mease SM Burgess SC Palmer L Abetz SA Martin, Patient Educ Couns 2008 73 1 114 120 10.1016/j.pec.2008.06.005 18640807
32. Gender variations in clinical pain experience. AM Unruh, Pain 1996 65 123 167 10.1016/0304-3959(95)00214-6 8826503
33. Sex differences in pain. KJ Berkley, Behav Brain Sci 1997 20 3 371 380 10097000
34. Do different factors explain self-rated health in men and women? AL Undén S Elofsson, Gend Med 2006 3 4 295 308 10.1016/S1550-8579(06)80218-4 17582371 (Pubitemid 46917058)
35. The role of gender in fibromyalgia syndrome. MB Yunus, Curr Rheumatol Rep 2001 3 2 128 134 10.1007/s11926-001-0008-3 11286669